Dr. Anabella  Villalobos Ph.D.

Head of Biotherapeutics & Medicinal Sciences

Dr. Mahalakshmi  Radhakrishnan M.D.

Chief Medical Officer & Group Senior Vice President

Ms. Natacha  Gassenbach

Chief Communication Officer & Head of Corporation Affairs

Dr. Ginger  Gregory

Executive Vice President & Chief HR Officer

Mr. Christopher A. Viehbacher

Pres, Chief Executive Officer & Director

Mr. Michael R. McDonnell CPA

Executive Vice President & Chief Financial Officer

Ms. Nicole  Murphy

Head of Pharmaceutical Operations & Technology

Ms. Susan H. Alexander Esq.

Executive Vice President, Chief Legal Officer & Sec.

Dr. Sanjay  Jariwala

Senior Vice President of Worldwide Medical

Ms. Robin C. Kramer

Senior Vice President & Chief Accounting Officer

Mr. Michael  Hencke

Head of Investor Relations

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

U.S. Wide-Moat Stocks On Sale - The March 2023 Heat Map

Biogen Q4 revenue was down 7% y/y. Zuranolone is a breakthrough depression therapy with an August 5, 2023, PDUFA date.

Biogen Should Resume Strong Growth With Zuranolone Approval

Biogen Inc. (NASDAQ:BIIB ) 43rd Annual Cowen Healthcare Conference Call March 6, 2023 9:50 AM ET Company Participants Christopher Viehbacher - Chief Executive Officer Conference Call Participants Philip Nadeau - Cowen & Company Philip Nadeau Welcome to the TD Cowen 43rd Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analyst here at Cowen.

Biogen Inc. (BIIB) 43rd Annual Cowen Healthcare Conference Conference (Transcript)

The FDA grants priority review to Biogen (BIIB) and Eisai's sBLA seeking traditional approval of Alzheimer's disease drug, Leqembi. The FDA decision is expected on Jul 6, 2023.

Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi

Medicare has agreed to provide broader coverage once Leqembi receives full FDA approval.

FDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July

Amyloid Gains Converts in Debate Over Alzheimer’s Treatments

The FDA Has Approved Eisai and Biogen's New Alzheimer's Therapy 

New Alzheimer’s Drug Approved by FDA, Promises to Slow Disease

Alzheimer’s Breakthrough Is Boost for Biogen, Eli Lilly 

Biogen, Eisai's Alzheimer's Data Confirm Benefit but Questions Loom

New Alzheimer’s Drug Shows Positive Results but Side Effects

Biogen's New Alzheimer's Drug Faces Its Next Test. 5 Big Questions.

Biogen in Pole Position After Roche's Alzheimer's Drug Disappoints

Biogen Names Viehbacher New CEO

Biogen Taps a New CEO. He Faces a Tough Road After Alzheimer's Flop. 

Volunteer Dies Testing Eisai-Biogen Alzheimer’s Drug During Study 

Biogen Lifts Profit Estimates as Investors Look to Alzheimer's Drug

Alzheimer’s Drugs Advance but Slowing Disease Remains a Challenge

New Alzheimer's Drug Success Was a Shock. Now There Are 5 Big Questions.

Biogen Soars 40% on Alzheimer’s Drug Trial. Mizuho Says the Stock Is a Buy.

Biogen to Pay $900 Million Over Alleged Physician Kickbacks

Netflix, Tesla, Biogen, and More of Wednesday’s Stock Market Movers

Alzheimer’s Patients Now Less Likely to Receive Biogen’s Aduhelm Treatment 

Biogen CEO to Resign After Alzheimer’s Drug Struggles

Biogen Searches for New CEO in Wake of Struggles With Alzheimer's Drug 

It's Lights Out for Biogen's Aduhelm

Medicare Limits Payments for Biogen’s Alzheimer’s Drug 

Biogen's Aduhelm Credibility Problem Deepens. Investors Are Paying the Price.

Biogen and Eisai Rewrite Alzheimer’s Drug Marketing Pact 

Medicare Proposal on Alzheimer’s Drug Draws Criticism From Drugmakers

Sage Antidepressant Trial Hits Its Target. Why the Stock Is Down.

Biogen Stock Drops as Results Fall Short. Sales of Alzheimer's Drug Disappoint.

Biogen to Sell Biosimilar-Venture Stake to Partner Samsung Biologics

Biogen Will Recruit Minority Participants for New Aduhelm Trial

Biogen, PayPal, Block, Ally Financial: What to Watch in the Stock Market Today

Biogen Trips Again on Alzheimer's Drug

Medicare to Pay for Biogen’s New Alzheimer’s Drug in Clinical-Trial Patients 

Biogen’s Alzheimer’s Drug Has Another Shot at Success

How Biogen Fumbled Aduhelm, Its Once-Promising Alzheimer’s Drug

Biogen Stock Plummets After Samsung Denies Report It Wants to Buy the Biotech

Biogen Halves Price of Alzheimer's Drug, Says It Will Slash Its Own Costs

Biogen Cuts Price for Alzheimer’s Drug Aduhelm by Half

Biogen Stock Slips After EU Regulator Has Doubts on Controversial Alzheimer's Therapy

Biogen Investigates Death of Aduhelm Patient 

Biogen’s New Alzheimer’s Drug Meets Slow Rollout 

Biogen’s Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock.

Apple iPhone Features Would Detect Depression, Cognitive Decline

Airbnb, Apache, Biogen: What to Watch When the Stock Market Opens Today

Biogen Stock Tumbled Because Its Alzheimer's Drug Rollout Isn't Going So Well

Biogen’s New Alzheimer’s Drug Beyond Reach for Many Patients 

VA Health System Won’t Cover Biogen’s Alzheimer’s Drug

Biogen Sees Heavy Patient Interest in  New Alzheimer’s Drug 

Medicare Is Already Deciding Whether to Limit Coverage of Biogen's Alzheimer's Drug

FDA Seeks Probe of Talks Between Staff, Biogen on Alzheimer’s Drug

Biogen Alzheimer’s Drug Will Exceed the $56,000 List Price for Many, Analysis Says 

Acknowledging Concerns Over Biogen's Alzheimer's Drug, FDA Asks for Investigation

FDA Narrows Suggested Uses for New Alzheimer’s Drug

FDA Narrows Its Label on Biogen's Alzheimer's Drug a Month After Approving It

FDA made a mistake in approving a questionable Alzheimer's drug, but Medicare could act to reduce false hopes and unethical profits

Biogen Stock Is Sliding. House Committees Will Investigate Its $56K Alzheimer's Drug.

Costly New Alzheimer’s Drug Could Force Medicare to Restrict Access 

Biogen’s Alzheimer’s Drug Opens Up a New Market. These Stocks Could Benefit if More Approvals Come.

A Third Expert Quits FDA Panel Over Approval of Biogen Alzheimer's Drug 

FDA’s Approval of Alzheimer’s Drug Leads to Third Adviser’s Resignation

GameStop, Clover Health, FuelCell Energy: What to Watch When the Stock Market Opens Today

The $56,000 Price of Biogen's Alzheimer's Drug Could Backfire

First Alzheimer’s Drug to Slow Disease Is Approved by FDA 

Biogen's Alzheimer's Drug Is Approved by the FDA 

Biogen Stock Gains Before Anticipated FDA Decision

What to Know About the FDA's Approval of Biogen's Alzheimer's Drug

FDA's Call on Alzheimer's Drug Is Coming. These Analysts Expect a Green Light.

Biogen’s Day of Reckoning Nears

Powered by AI

Biogen Inc.

298.66